Servier and MiNA Therapeutics sign €220m dealFrench Servier SA and the UK’s MiNA Therapeutics Ltd have entered into a R&D partnership to identify and develop small activating RNAs (saRNA) to treat neurological disorders. more ➔
LSP leads €21m round into Neurent MedicalIrish life sciences company Neurent Medical has closed a €21m Series B investment co-led by LSP as well as Atlantic Bridge with participation of Fountain Healthcare Partners. more ➔
Janssen presents one-shot COVID-19 vaccine dataJ&J subsidiary Janssen Pharma has presented updated Phase I/II antibody levels supporting a single shot administration for its COVID-19 vaccine. more ➔
German researchers find reason for remdesivir’s inefficiencyGerman Researchers have unraveled how remdesivir interferes with the viral RNA polymerase and why it does not block SARS-CoV-2 completely. more ➔
LSP reports first closing of dementia fundEuropean life sciences investors LSP has closed a new fund to fight dementia at €50m. more ➔
Valneva in talks with EU about 60 million vaccine dosesFrench Valneva SE announced it is in advanced discussions with the European Commission (EC) for the supply of up to 60 million doses of its COVID-19 vaccine, VLA2001. more ➔
Immunocore bags US$75m in Series C roundImmuno-oncology specialist Immunocore plc announced the completion of a $75m Series C private financing round. more ➔
EU approves second COVID-19 vaccineFollowing a recommendation by the European Medicines Agency (EMA), the European Commission has approved a second vaccine against the novel coronavirus SARS-CoV-2. more ➔
Angelini Pharma to take over Arvelle TherapeuticsItalian Angelini Pharma and Swiss CNS disease specialist Arvelle Therapeutics have entered into a definitive merger agreement. more ➔
COVID-19 test gives results within minutesUniversity of Birmingham researchers have invented a COVID-19 RNA test that reduces testing time from 30 minutes to under five, and delivers accurate results. more ➔
